文献速递主动脉疾病

日间血管腔内动脉瘤修复术的可行性与成本分析

Feasibility and Cost Analysis of Ambulatory Endovascular Aneurysm Repair.
PubMed 文献 · J Endovasc Ther · 2022-11-08

本研究在两家学术中心回顾性比较2016年4月至2018年12月择期血管腔内动脉瘤修复术(EVAR)患者中,计划日间EVAR(a-EVAR)与住院EVAR(i-EVAR)的成本。共纳入170例,a-EVAR成功率为84%(84/100);a-EVAR组30天和1年总成本分别降低27%和21%,均未达统计学显著;85岁以下患者和男性在30天成本分别降低34%(p=0.027)和33%(p=0.035)。结论为经选择的患者同日出院可行且成功,85岁以下患者和男性在日间EVAR中具有短期成本获益,且未增加并发症或再干预。

要点

  • a-EVAR成功率为84%(84/100),急诊就诊、再入院和再干预至1年与i-EVAR相似(均p=NS)。
  • a-EVAR组30天和1年总成本分别降低27%和21%,均未达统计学显著。
  • 85岁以下患者和男性行a-EVAR的30天成本分别降低34%(p=0.027)和33%(p=0.035)。

核心结论

  • 经选择的患者同日出院可行且成功;85岁以下患者和男性在日间EVAR中具有短期成本获益,且未增加并发症或再干预。

研究设计与样本

  • 回顾性队列研究,纳入2016年4月至2018年12月在两家学术中心连续接受择期EVAR的患者,计划a-EVAR者与i-EVAR者比较,共170例。

主要发现

  • a-EVAR成功率为84%(84/100);a-EVAR组年龄76±8岁,i-EVAR组78±9岁;a-EVAR组平均动脉瘤直径56±6 mm,i-EVAR组59±6 mm。
  • 急诊就诊、再入院和再干预至1年两组相似(均p=NS)。
  • a-EVAR组30天和1年总成本分别降低27%和21%,均未达统计学显著。
  • 85岁以下患者和男性行a-EVAR的30天成本分别降低34%(p=0.027)和33%(p=0.035)。
  • 大多数患者接受经皮EVAR(>94%)和脊髓麻醉(>84%)。

临床怎么用

  • 作者认为,经选择的患者同日出院可行且成功;85岁以下患者和男性在日间EVAR中具有短期成本获益,且未增加并发症或再干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to compare the costs of ambulatory endovascular aneurysm repair (a-EVAR) and inpatient EVAR (i-EVAR) at up to 1-year of follow-up. MATERIALS AND METHODS: A retrospective cohort study of consecutive patients undergoing elective EVAR between April 2016 and December 2018 at two academic centers. Patients planned for a-EVAR were compared with i-EVAR. Costs at 30 days and 1 year were extracted. These included operating room (OR) use, bed occupancy, laboratory and imaging, emergency department (ED) visits, readmissions, and reinterventions. Baseline characteristics were compared. Multiple regression model was used to identify predictors of increased EVAR costs. Repeated measures analysis of variance (ANOVA) was used to compare cost differences at 30 days and 1 year via an intention-to-treat analysis. Bonferroni post hoc test compared between-group differences. A p value<0.05 was considered statistically significant. RESULTS: One hundred seventy patients were included. Most underwent percutaneous EVAR (>94%) under spinal anesthesia (>84%). Ambulatory endovascular aneurysm repair was successful in 84% (84/100). Ambulatory endovascular aneurysm repair patients (76±8 years) were younger than i-EVAR (78±9 years). They also had a smaller mean aneurysm diameter (56±6 mm) compared with i-EVAR (59±6 mm). Emergency department visits, readmissions, and reinterventions were similar up to 1 year (all p=NS). Ambulatory endovascular aneurysm repair costs showed a non-statistically significant reduction in total costs at 30 days and 1 year by 27% and 21%, respectively. Patients younger than 85 years and males had a 30-day cost reduction by 34% (p=0.027) and 33% (p=0.035), respectively with a-EVAR. CONCLUSIONS: Same-day discharge is feasible and successful in selected patients. Patients younger than 85 years and males have a short-term cost benefit with EVAR done in the ambulatory setting without increased complications or reinterventions. CLINICAL IMPACT: This study shows the overall safety of ambulatory EVAR with proper patient selection. These patient had similar post-intervention complications to inpatients. Same day discharge also resulted in short-term reduction in costs in male patients and patients younger than 85 years.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Naiem AA, Doonan RJ, Guigui A, et al. Feasibility and Cost Analysis of Ambulatory Endovascular Aneurysm Repair. J Endovasc Ther. 2022. PMID: 36346006. doi:10.1177/15266028221133694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。